Understanding the type of arthritis, its causes, and management options is the first step toward living well with the condition.

Rheumatoid arthritis is a chronic autoimmune disease that affects millions of people worldwide. This disease prompts the ...

The developers of sustained acoustic medicine technology and the sam® wearable ultrasound device continue mission of ...

Tom Nolan reviews this week’s research GLP-1 receptor agonists, now widely used for diabetes, cardiovascular disease, and weight loss, seem to be as effective for these indications regardless of age, ...

The FDA granted the approval following findings from the pivotal POETYK PsA-I and POETYK PsA-II Phase III studies.

RA can affect your lifespan in various ways related to cardiovascular disease, lung disease, infection, depression, and ...

Joint pain is often dismissed as aging, overuse or a minor injury. But for some people it is the first sign of inflammatory ...

Up to 30% of children with juvenile arthritis develop uveitis, an eye inflammation that can damage vision. New research highlights immune cells as treatment targets.

Early intensive treatment for PsA with csDMARDs or 6 months of TNFi is superior to standard step-up care, and better outcomes ...

Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries and/or associated companies) announced that the US ...

The FDA will review the supplemental Biologics License Application for tildrakizumab for the treatment of adults with active PsA.

The manufacturer of the interleukin-23 inhibitor tildrakizumab (Ilumya), Sun Pharma, announced today that the FDA has ...